title: Expression of killer cell inhibitor receptors on immunocompetent cells with relation to graft-versus-host disease after hematopoietic stem cell transplantation.
abstract: The study was aimed at the exploration of relationship between T cells expressing killer cell inhibitor receptors (KIR, CD158 and CD94) and graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation. The expression rates of CD158a, CD158b and CD94 on T cells and NK cell were detected by flow cytometry and donor/recipient HLA-Cw was analyzed using PCR after peripheral blood stem cell transplantation (PBSCT) and umbilical cord blood transplantation (UCBT). After both PBSCT and UCBT, the rates of CD3(+)CD158a(+) and CD3(+)CD158b(+) T cells increased, especially the rate of CD8(+)CD158b(+) T cells. In both acute and chronic GVHD groups, the rate of CD3(+)CD158b(+) T cells increased, especially in acute GVHD. The CD94 mainly expressed on CD3(+)CD8(+) T cells. The percentage of the expression of CD94 on CD4(+) and CD8(+) cells after UCBT and PBSCT increased significantly. The expression of KIR in GVHD (early stage of transplantation) increased but the expression of KIR in chronic GVHD (advanced stage of transplantation) decreased. Five patients who HLA-Cw matched had no severe GVHD. In four patients who underwent allo-PBSCT and UCBT from related HLA-matched donors, only 2 patients had no aGVHD. Four patients underwent transplantation from unrelated HLA-matched donors had GVHD. These observations suggested that there is some relationship between GVHD and KIR expression on T cells. CD158b might be an inhibitory molecule of T cell activated at early stage after transplantation. Understanding the mechanism of GVHD with the expression of KIR on T cells, especially those binding the HLA-Cw might shed light on the establishment of the specific immunotolerance for the prevention of GVHD. To pay attention to HLA-Cw typing is very important to reduce GVHD and increase GVL effect in related or unrelated HLA-matched transplantation.
authors.affiliation: Department of Pathophysiology, The Sun Yat-Sen University of Medical Sciences, Guangzhou, China. duanln@163.net
authors.forename: Lian-Ning
authors.initials: LN
authors.lastname: Duan
authors.forename: Chun
authors.initials: C
authors.lastname: Chen
authors.forename: Shao-Liang
authors.initials: SL
authors.lastname: Huang
authors.forename: Jian-Pei
authors.initials: JP
authors.lastname: Fang
authors.forename: Jing
authors.initials: J
authors.lastname: Wei
authors.forename: Rong
authors.initials: R
authors.lastname: Bao
authors.forename: Yan
authors.initials: Y
authors.lastname: Li
authors.forename: Hong-Xing
authors.initials: HX
authors.lastname: Han
authors.forename: Shu-Nong
authors.initials: SN
authors.lastname: Li
mesh_terms: D015703:Antigens, CD / Q000032:analysis; D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis; D005838:Genotype; D006086:Graft vs Host Disease / Q000209:etiology*; D015236:HLA-C Antigens / Q000235:genetics; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D037181:Lectins, C-Type; D011971:Receptors, Immunologic / Q000032:analysis*; D015375:Receptors, Interleukin-2 / Q000032:analysis; D054340:Receptors, KIR; D054342:Receptors, KIR2DL1; D054344:Receptors, KIR2DL3; D013601:T-Lymphocytes / Q000276:immunology*; D000099192:CD69 Antigens
chemical_list: D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D015236:HLA-C Antigens; D037181:Lectins, C-Type; D011971:Receptors, Immunologic; D015375:Receptors, Interleukin-2; D054340:Receptors, KIR; D054342:Receptors, KIR2DL1; D054344:Receptors, KIR2DL3; D000099192:CD69 Antigens